作者:Raffaella Cincinelli、Loana Musso、Roberto Artali、Mario B. Guglielmi、Ilaria La Porta、Carmela Melito、Fabiana Colelli、Francesco Cardile、Giacomo Signorino、Alessandra Fucci、Martina Frusciante、Claudio Pisano、Sabrina Dallavalle
DOI:10.1371/journal.pone.0205018
日期:——
hybrid molecules targeting simultaneously topoisomerase I and HDAC were designed. In particular, a selected multivalent agent containing a camptothecin and a SAHA-like template showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range. Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted
最近的研究表明,在联合疗法中,HDAC抑制剂与喜树碱衍生物具有协同作用。为了利用这种协同作用,设计了同时靶向拓扑异构酶I和HDAC的新杂合分子。特别是,含有喜树碱和SAHA样模板的选定多价药物表现出广谱的抗增殖活性,IC50值在纳摩尔范围内。初步的体内结果表明对CD-1裸鼠原位异种移植的人间皮瘤原代细胞MM473有很强的抗肿瘤活性,并且具有很高的耐受性。